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Introduction: High resolution vessel wall MRI (VW-MRI) has enabled to characterize
intracranial atherosclerosis (ICAS). We studied to identify the factors for enhancement of
ICAS in VW-MRI in patients with acute ischemic stroke.
Methods: Consecutive patients with acute ischemic stroke or TIA who underwent
VW-MRI between January 2017 and December 2017 were included. Enhancement on
VW-MRI was defined as an increase in intensity on contrast-enhanced T1-weighted
sequence. We compared the clinical and the radiologic findings between patients with
wall enhancement and those without wall enhancement.
Results: Of the 48 patients with ICAS, 28 patients revealed enhancement on VW-MRI.
Patients with enhancement were more likely to have severe stenotic lesions and
higher levels of total cholesterol, triglycerides, low-density cholesterol, Apo (b), and
Apo (b)/Apo (a) lipoprotein ratio (p < 0.05). Multivariable analysis demonstrated that
total cholesterol (OR: 5.378, 95% CI, 1.779–16.263), triglycerides (OR: 3.362, 95% CI,
1.008–11.209), low density lipoprotein cholesterol (OR: 4.226, 95% CI, 1.264–14.126),
Apo (b) lipoprotein (OR: 3639.641, 95% CI, 17.854–741954.943) levels, and Apo
(b)/Apo (a) lipoprotein ratio (OR, 65.514; 95% CI, 1.131–3680.239) were independently
associated with enhancement of ICAS. High-density lipoprotein cholesterol and Apo
(a) lipoprotein levels were not significantly different between the patients with wall
enhancement and those without wall enhancement.
Conclusions: The presence and severity of enhancement of ICAS was significantly
associated with dyslipidemic conditions. These results suggest that strict lipid
modification should be achieved for the management of ICAS.
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INTRODUCTION
Ischemic stroke is a major cause of mortality and morbidity
worldwide (1). Atherosclerosis, in particular, intracranial
atherosclerosis (ICAS), is recognized as one of the most common
etiological factors of ischemic stroke accounting for 30–50%
of the ischemic cerebrovascular events (2). Moreover, ischemic
stroke attributable to ICAS is known to be associated with
an increased risk of poor functional outcomes after stroke,
cognitive impairment, and vascular death (3). Precise in vivo
characterization of ICAS is crucial, as this knowledge enables the
clinicians to better stratify the stroke risk for individual patients
and to plan therapeutic strategies accordingly.
Conventionally, clinicians have focused primarily on
detection and estimation of the degree of luminal stenosis by
using luminography techniques such as digital subtraction
angiography or magnetic resonance angiography (MRA).
However, luminography alone is insufficient to fully determine
the histopathologic composition and instability of the plaque
(4, 5). Currently, the advent of high resolution vessel wall
magnetic resonance imaging (VW-MRI) has enabled clinicians
to differentiate among various intracranial vasculopathies and to
characterize the vulnerability of ICAS plaque, which is thought
to be the culprit lesion of ischemic events, and the degree of
luminal stenosis (6–9). Among the VW-MRI findings, contrast
enhancement of the ICAS plaque is increasingly being reported
as a reliable marker of plaque vulnerability. It also tends to be
predictive of future cerebrovascular events (4, 10, 11). However,
the factors for the presence or extent of arterial wall enhancement
on VW-MRI are not fully understood (12, 13).
In the present study, we aimed to identify the factors for




We performed a retrospective analysis of all the patients with
ischemic stroke admitted to Severance Stroke Center for the
treatment of cerebral infarction or transient ischemic attack
within seven days after the onset of symptoms between January
2017 and December 2017. At the time of admission, all the
patients were thoroughly evaluated to record the demographic
data, medical history, clinical manifestations, and vascular risk
factors (14). All patients underwent brain computed tomography
and/or magnetic resonance imaging with cerebral angiographic
studies, standard blood tests, and 12-lead electrocardiography.
Cerebral angiographic studies including digital subtraction
angiography, MRA, or computed tomography angiography
covering intracranial arterial beds, the proximal carotid portion,
and vertebral orifice were performed. Most of the patients were
admitted to a stroke unit and were monitored continuously
with electrocardiography during their stay (average 4.9 days).
Holter monitoring was also performed if a cardiac embolism
was suspected based on the infarction pattern, patient’s age,
or previous cardiac history. Transesophageal echocardiography
was included in the routine examination, unless it could not be
performed due to patient’s condition or the failure to obtain an
informed consent.
Among the patients admitted during the study period,
we included patients who underwent VW-MRI during
hospitalization. Patients were excluded if they had (1) at
least one of the high risk potential cardiac sources of embolism
based on Trial of ORG 10272 in Acute Stroke Treatment
classification (15), (2) nonatherosclerotic vasculopathies such
as aortic dissections, vasospasm, vasculitis, or moyamoya
disease, and (3) poor quality of imaging data. The present
study was approved by the institutional review board
of Severance Hospital, Yonsei University Health System.
Informed consent was waived due to the retrospective nature of
the study.
MR Imaging Analysis
All the scans were performed using a Philips Ingenia 3.0T Cx
MR scanner (Philips Medical systems, Best, The Netherlands)
with a 32-channel head coil. TOF-MRA scan was primarily
used to find the location and the degree of stenosis in ICAS.
The neuroradiologist (J.C.) selected the site of evaluation and
the appropriate protocol based on the clinical presentation
and TOF-MRA findings. For vessel wall evaluation, high
resolution 3-dimensional proton-density (3D-PD), pre/post-
contrast enhanced T1WI with black-blood techniques (3D turbo
spin echo sequence with improved motion-sensitized driven-
equilibrium preparation) (T1-BB pre/post) were performed
using the following parameters: (1) TOF-MRA: TR−19ms,
TE−3.5ms, FOV−210 × 210mm, matrix size−640 × 330, slice
thickness−1.2mm (interpolated to 0.6mm), 9.6 cm coverage on
axial plane which covered all intracranial major arteries with
maximum intensity projection reconstruction, and acquisition
time−5min 10 sec. (2) 3D-PD: TR−1,800ms, TE−37.4ms,
FOV−180 × 180mm, matrix size−384 × 384mm, slice
thickness−0.5mm (interpolated to 0.3mm), 4 cm coverage
on coronal plane with axial and sagittal reconstruction, and
acquisition time−9min 37 sec. (3) T1-BB pre/post: TR−650ms,
TE−34.8ms, FOV−180× 180mm, matrix size−304× 304mm,
slice thickness−0.6mm (interpolated to 0.3mm), 4 cm coverage
on coronal plane with axial and sagittal reconstruction, and
acquisition time−8min 21 s.
Clinical and Imaging Variables
We collected the patient data on vascular risk factors such
as hypertension, diabetes, dyslipidemia, body mass index
(kg/m2), metabolic syndrome according to National Cholesterol
Education Program Expert Panel and Adult Treatment Panel
III criteria, current smoking, prior history of ischemic heart
disease, ischemic stroke, or peripheral artery occlusive disease,
and prior medication status. We defined hypertension when
systolic blood pressure was higher than 140 mmHg or patients
prescribed medication, and also defined diabetes or dyslipidemia
when patients had medication or their lab findings were met
the diagnostic criteria. We also investigated the laboratory
data including complete blood count, blood urea nitrogen,
creatinine, serum protein and albumin level, fasting glucose,
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HbA1c, erythrocyte sedimentation ratio, C-reactive protein, D-
dimer, creatinine kinase, fibrinogen levels, and lipid profiles (total
cholesterol, triglycerides, high-density lipoprotein cholesterol
[HDL-C], low-density lipoprotein cholesterol [LDL-C], non-
HDL cholesterol, Apo [b] lipoprotein, Apo [a] lipoprotein, and
Apo [b]/Apo [a] ratio). The lipid profile was drawn from the
antecubital vein 8 hours after an overnight fast. All blood tests
were performed at the Department of Laboratory Medicine,
Yonsei University College of Medicine. Total cholesterol,
triglyceride, HDL-C, and LDL-C was Enzymatic methods using
Atellica CH 930 Analyzer (Siemens Healthcare Diagnostics,
Marburg, Germany) and Apo (b) and Apo (a) lipoprotien was
done by immunoturbidimetric assay using Cobas c702 (Roche
Diagnostics, Switzerland). Stroke severity was assessed using the
National Institutes of Health Stroke Scale.
We investigated the enhancement of the culprit intracranial
plaque, which was the lesion within the same vascular territory
as that of the stroke. In the case of multiple lesions, we
decided culprit lesion within the same vascular territory as that
of the major infarctions. When a patient had a lesion with
the enhancement, the degree of enhancement was classified
as mild to moderate or strong, based on comparison with
the signal intensity of the pituitary stalk. In addition, we
collected the data on the presence of high T1 signal of
plaque, enhancement type (eccentric or non-eccentric) and
reconstruction index (the ratio of the outer wall diameter at
the lesion site to that at the contralateral normal site) among
patients with enhancement. Based on the degree of stenosis
of ICAS, we divided patients into four groups including no
stenosis, mild to moderate stenosis (< 50%), severe stenosis
(≥ 50%), and occlusion. For categorizing the severity of
arterial stenotic lesions, the degree of stenosis was measured in
culprit arterial segment based on the Warfarin vs. Aspirin for
Symptomatic Intracranial Disease method (16). The radiologic
findings were interpreted by a radiologist and a neurologist
(J.C and N.E.W.) who were blinded to clinical information. In
case of a discrepancy, the final decision was made by a third
reviewer (Y.D.K).
Statistical Analysis
Statistical analyses were performed using the Windows SPSS
package (version 24.0, IBM Corp., Armonk, NY, USA) and
R version 3.4.2 (http://www.R-project.org). The analyses were
performed using the independent t-test, one way analysis
of variance, Mann-Whitney U test, or the Kruskal-Wallis
test for the continuous variables and the χ2 test or the
Fisher’s exact test for categorical variables, as appropriate.
Spearman correlation analysis was used to investigate the
relationship between reconstruction index and continuous
variables. When we investigated the trend of lipid levels by
the degree of enhancement, one way analysis of variance
using trend contrasts was used. To determine the independent
factors for the enhancement of ICAS on VW-MRI, multiple
logistic regression analysis was used with adjustment for
potential confounders with p < 0.05 in the univariable
analysis. A two-tailed p-value less than 0.05 was considered
statistically significant.
TABLE 1 | Baseline characteristics of patients and comparison between patients





(−) (n = 20)
Wall
enhancement
(+) (n = 28)
p
Age, y 57.0 ± 16.4 53.5 ± 18.8 59.5 ± 14.2 0.21
Male sex 31 (64.6) 13 (65.0) 18 (64.3) 0.86
Body mass index,
kg/m2
24.8 ± 3.4 24.6 ± 4.2 24.9 ± 2.9 0.81
Hypertension 28 (58.3) 9 (45.0) 19 (76.9) 0.11
Diabetes 14 (29.2) 7 (35.0) 7 (25.0) 0.46
Hyperlipidemia 11 (22.9) 2 (10.0) 9 (32.1) 0.09
Metabolic syndrome 1 (2.1) 0 (0.0) 1 (3.6) 1
Smoker 25 (52.1) 10 (50.0) 15 (53.6) 0.81
Previous ischemic
heart disease
13 (27.1) 9 (45.0) 4 (14.3) 0.02
Peripheral arterial
occlusive diseases
2 (4.2) 1 (5.0) 1 (3.6) 1
Previous ischemic
stroke
13 (27.1) 8 (40.0) 5 (17.9) 0.09




No stenosis 8 (16.7) 8 (40.0) 0 (0.0)
Mild to moderate
stenosis (< 50%)
13 (27.1) 1 (5.0) 12 (49.3)
Severe stenosis (≥
50%)
19 (39.6) 4 (20.0) 15 (53.6)




4.7 ± 1.1 4.1 ± 1.2 5.2 ± 0.8 <.001








2.9 ± 0.9 2.4 ± 0.9 3.2 ± 0.8 0.001
Non-HDL cholesterol,
mmol/L
3.5 ± 1.0 2.9 ± 1.1 4.0 ± 0.8 <0.001
Apo (a) lipoprotein,
g/L
1.4 ± 0.3 1.3 ± 0.2 1.4 ± 0.3 0.17
Apo (b) lipoprotein,
g/L
1.1 ± 0.3 0.9 ± 0.3 1.2 ± 0.2 <.001
Apo (b)/Apo (a) ratio 0.8 ± 0.2 0.7 ± 0.2 0.9 ± 0.2 0.003
Blood urea nitrogen,
mmol/L
5.8 ± 2.1 5.7 ± 1.9 5.9 ± 2.2 0.86
Creatinine, µmol/L 69.1 ± 22.3 71.3 ± 15 67.5 ± 26.5 0.58
Albumin, g/L 42.6 ± 3.2 42.8 ± 3.2 42.4 ± 3.2 0.73
Protein level, g/L 69.8 ± 5.2 69.4 ± 5.8 70 ± 4.8 0.66
Creatine kinase,
µkat/L
2.3 ± 2.1 3 ± 2.8 1.7 ± 1.1 0.06
C-reactive protein,
nmol/L
44.7 ± 169.5 74.6 ± 261.3 23.6 ± 37.2 0.32
D-dimer, nmol/L 1167.5 ±
1468.4
1616 ± 2008.7 847.2 ± 811.5 0.12
(Continued)
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(−) (n = 20)
Wall
enhancement






0.008 ± 0.003 0.008 ± 0.002 0.82
Hemoglobin, g/L 147.6 ± 18.8 144.3 ± 18.3 150 ± 19.1 0.31
Platelet count 229.4 ± 52.6 215.9 ± 69.3 239.1 ± 34.8 0.18
HbA1c 0.06± 0.01 0.06 ± 0.01 0.06 ± 0.01 0.26
Fasting glucose,
mmol/L




18.3 ± 15.3 15.6 ± 14.8 20 ± 15.7 0.35
Fibrinogen level,
µmol/L
8.8 ± 2.3 8.2 ± 1.7 9.3 ± 2.6 0.11
Data are presented as numbers (%) or mean ± standard deviation.
RESULTS
Out of the 79 patients who had acute ischemic stroke and who
underwent the VW-MRI during the study period, we included
48 patients after excluding 3 patients with high risk potential
cardiac sources of embolism, 26 patients with nonatherosclerotic
vasculopathies, and 2 patients with poor quality of imaging data.
The baseline characteristics are presented in Table 1. The
mean age was 57.0 years and 64.6% (31/48) of the patients were
male. Twenty patients had no arterial lesion with enhancement,
while 28 patients showed enhancement (8 with mild to moderate
enhancement and 20 with strong enhancement) on VW-MRI.
The location of the arterial segments with enhancement was
middle cerebral artery in 16 patients, vertebral and basilar artery
in 8 patients, and distal internal carotid artery in 2 patients.
Patients with enhancement were more likely to have
severe stenotic lesions and higher levels of total cholesterol,
triglycerides, LDL-C, non-HDL cholesterol, Apo (b), and Apo
(b)/Apo (a) lipoprotein ratio (p <.05) (Table 1, Figures 1, 2).
Moreover, patients with enhancement were less likely to have
a prior history of ischemic heart disease or a history of statin
use. After investigating the relationship between the severity of
enhancement and the lipid indices, a gradual increase in the
lipid level was noted with increase in the degree of enhancement
(Figure 3). However, there was no significant difference in HDL-
C and Apo (a) lipoprotein levels with respect to enhancement
of ICAS.
Multivariable analysis adjusting prior history of ischemic
heart disease, prior statin use, and the presence of severe
steno-occlusive lesions demonstrated that total cholesterol (OR:
5.378, 95% CI, 1.779–16.263), triglyceride (OR: 3.362, 95%
CI, 1.008–11.209), LDL-C (OR: 4.226, 95% CI, 1.264–14.126),
non-HDL cholesterol (OR: 4.928, 95% CI, 1.519–15.982), Apo
(b) lipoprotein (OR: 3639.641, 95% CI, 17.854–741954.943)
levels, and Apo (b)/Apo (a) lipoprotein ratio (OR: 65.514,
95% CI, 1.131–3680.239) were independently associated with
enhancement of ICAS (Table 2). However, HDL-C and Apo
(a) lipoprotein levels were not significantly different between
patients with enhancement and those without enhancement
(Table 2).
The presence of enhancement tended to be related to the lipid
profiles regardless of age (> 57 years [median age of our study
population] vs. ≤ 57 years) or sex (Supplementary Table 1),
although several results related with triglyceride, non-HDL,
Apo (b)/Apo (a) ratio did not reach statistical significance.
When we investigated which factor affected high T1 signal,
enhancement type, or reconstruction index, the presence of high
T1 signal intensity was associated with platelet count (p = 0.02)
and severe steno-occlusive lesion (p = 0.024), while eccentric
enhancement was related with severe stenosis (p = 0.021) and
blood urea nitrogen (p = 0.026). However, these findings of
VW-MRI were not associated with the dyslipidemic condition
(Supplementary Tables 2, 3).
DISCUSSION
In the present study, we aimed to identify the potential factors
for enhancement of the culprit plaque of ICAS. We observed
that the presence of intracranial arterial culprit plaque with
enhancement on VW-MRI was associated with higher levels
of total cholesterol, triglycerides, LDL-C, non-HDL cholesterol,
Apo (b) lipoprotein, and Apo (b)/Apo (a) lipoprotein ratio (the
so called “bad types of cholesterol”). The levels of HDL-C and
Apo (a) lipoprotein were not significantly different between
patients with enhancement and those without enhancement.
These associations remained statistically significant even after
adjusting for potential confounders. These findings indicated that
the enhancement of ICAS was independently associated with
dyslipidemic conditions. Moreover, there was a gradual increase
in these lipid indices with increase in the degree of enhancement,
indicating that the degree of ICAS enhancement is dependent on
the severity of dyslipidemia.
Accumulating evidence suggests that luminal stenosis alone
is not sufficient to fully explain the characteristics of ICAS
(6–8) in terms of the composition or the activity of the
culprit plaque (4, 5). In the early stages of atherosclerosis,
the accumulation of plaque burden could take place without
significant luminal narrowing. Such an accumulation is not
detectable by conventional luminography techniques. However,
this plaque can cause ischemic stroke when it is highly vulnerable
(17, 18). This finding has led researchers to expand their focus
beyond stenosis and toward the plaque morphology or plaque
instability in an attempt to identify more accurate imaging
markers to predict the risk of stroke related to ICAS (17). VW-
MRI can be a promising technique for reliably imaging the
intracranial arterial wall with superior soft tissue contrast and
spatial resolution (9).
Recent studies have suggested that vessel wall enhancement on
VW-MRImay be indicative of vulnerable or symptomatic plaque,
as it is commonly associated with multiple embolic infarctions
and has approximately four times higher recurrent stroke risk
(30% annual stroke risk) in future (4, 10, 11). However, the factors
for enhancement of the culprit plaque of ICAS in patients with
Frontiers in Neurology | www.frontiersin.org 4 June 2020 | Volume 11 | Article 580
Woo et al. Factors for Enhancement of ICAS
FIGURE 1 | A 62-year-old male patient presented with right hemiparesis with low-density cholesterol, total cholesterol, and Apo (b) levels of 67 mmol/L, 113 mmol/L,
75.5 g/L, respectively. (A) Axial DWI shows a high signal intensity lesion in the left corona radiata region. (B) TOF-MRA shows mild stenosis in the left middle cerebral
artery (proximal M1, arrow). (C) Pre-contrast 3-dimensional proton-density black-blood magnetic resonance images. (D) The post-contrast images (left: coronal plane,
right: sagittal plane) show eccentric wall thickening (arrow) without enhancement.
recent symptomatic ischemic stroke have not yet been thoroughly
investigated. Some reports have claimed that the risk factors for
atherosclerotic process such as age, hypertension, or dyslipidemia
may induce development and proliferation of the vasa vasorum
(19), which subsequently results in the ICAS related arterial
wall enhancement (20–22). Therefore, we aimed to evaluate
the potential association between ICAS plaque enhancement
and vascular risk factors including dyslipidemic conditions. We
hypothesized that the enhancing lesion on VW-MRI is suggestive
of plaque hemorrhage, neovascularization, or inflammation (23),
and the lipid metabolism may play an important role in this
process (24). Our analysis showed that triglycerides, LDL-C, non-
HDL cholesterol, and Apo (b) lipoprotein (the so-called “bad
cholesterols”) were independent and significant risk factors for
plaque enhancement on VW-MRI, while the other risk factors for
atherosclerosis were not associated with the plaque enhancement
of ICAS. Moreover, we found a dose-dependent relationship
between lipid levels and the degree of enhancement, indicating
that dyslipidemic conditions play an important role in ICAS and
subsequent stroke.
Contrast enhancement of atherosclerotic plaque was
suggestive of a rich vascular supply into the plaque and
enhanced endothelial permeability. In previous MRI studies of
histopathologically confirmed cervical artery atherosclerosis, the
plaque enhancement was significantly associated with the loose
fibrous cap, neovascularization in the adventitia of the artery,
macrophages, and increased endothelial permeability (25–27).
Compared with extracranial atherosclerosis, investigating
the ICAS plaque enhancement using vessel-wall imaging is
quite challenging, mainly due to the difficulty of performing
histologic validation in ICAS. Therefore, the pathophysiology,
composition, and vulnerability of the ICAS plaque behind the
enhancement are merely based on the assumption of imaging
features of ICAS. Moreover, the lessons learned from the
extracranial atherosclerosis cannot be directly extrapolated to
ICAS, as the histological features of intracranial vessels are
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FIGURE 2 | A 40-year-old male patient presented with right hemiparesis and aphasia with low-density cholesterol, total cholesterol, and Apo (b) levels of 178 mmol/L,
225 mmol/L, and 137 g/L, respectively. (A) Axial DWI shows a high signal intensity lesion in the left parietal region. (B) TOF-MRA shows severe stenosis in the left
middle cerebral artery (proximal M1, arrow). (C) Pre-contrast 3-dimensional proton-density black-blood magnetic resonance images. (D) Post-contrast images (left:
coronal plane, right: sagittal plane) show eccentric wall thickening (arrow) with enhancement.
different from those of the carotid arteries in that it has ICAS
has denser internal elastic lamina and less abundant adventitia
with external elastic lamina (28). However, in the process of
ICAS plaque formation, development and proliferation of the
vasa vasorum related to aging and atherosclerotic process could
also occur, subsequently leading to arterial wall enhancement, as
shown in carotid plaques (19, 29).
In the present study, HDL and Apo (a) lipoprotein were
not related with the enhancement of ICAS. Some studies
investigating the association between lipid profiles and ICAS in
the Asian population suggested that the burden of ICAS could be
affected more by LDL-C, total cholesterol, non-HDL cholesterol,
or Apo (b)/Apo (a) lipoprotein ratio rather than HDL-C (30–
33). High levels of total cholesterol or high Apo (b)/Apo (a)
lipoprotein ratio were reported to be associated with progression
of ICAS (34). Our results were consistent with these previous
findings, which suggested that the vulnerability of ICAS could be
affected more by non-HDL cholesterol or Apo (b) lipoprotein,
than HDL or Apo (a) lipoprotein.
Considering the relationship between the enhancement of
ICAS and higher lipid levels, lowering the lipid levels by means of
intensive statin therapy could decrease the chance of vulnerable
plaque development. Previous studies have suggested that
intensive statin therapy tends to be associated with lower volume
of ICAS enhancement and thus, may be helpful in preventing
the embolic occlusion (20). Given the association between the
enhancement of ICAS and future risk for recurrent stroke, our
findings suggest the need for intensive lipid lowering therapy in
stroke management. There is no target level specific to ICAS with
history of stroke. However, lipid-lowering therapy using statin
with or without ezetimibe with the target of LDL-C < 70 mg/dL
or non-HDL cholesterol < 100 mg/dL may be a viable option.
It is the target recommended for ‘patients with atherosclerotic
cardiovascular disease with very high risk’ according to recent
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FIGURE 3 | Degree of enhancement of intracranial atherosclerosis according to lipid levels. (A) Total cholesterol. (B) Triglyceride. (C) Low density lipoprotein
cholesterol. (D) High density lipoprotein cholesterol. (E) Non-HDL cholesterol. (F) Apolipoprotein A. (G) Apolipoprotein B. (H) ApoB/ApoA ratio. Group 1: no
enhancement, Group 2: mild to moderate enhancement, Group 3: strong enhancement.
TABLE 2 | Factors for enhancement of ICAS on VW-MRI.
Univariable analysis Multivariable analysis*
Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Total cholesterol, mmol/L 3.123 (1.544–6.317) 0.002 5.378 (1.779–16.263) 0.003
Triglyceride, mmol/L 2.515 (1.031–6.137) 0.04 3.362 (1.008–11.209) 0.05
High density lipoprotein cholesterol, mmol/L 3.672 (0.444–30.336) 0.227 8.172 (0.795–83.979) 0.08
Low density lipoprotein cholesterol, mmol/L 3.236 (1.458–7.179) 0.004 4.226 (1.264–14.126) 0.02
Non-HDL cholesterol, mmol/L 3.164 (1.525–6.562) 0.002 4.928 (1.519–15.982) 0.008
Apo (a) lipoprotein, g/L 5.377 (0.470−61.507) 0.18 9.862 (0.768–126.555) 0.08
Apo (b) lipoprotein, g/L 181.794 (9.412–3511.318) 0.001 3639.641 (17.854–741954.943) 0.003
Apo (b) lipoprotein/Apo (a) lipoprotein 86.707 (3.301–2277.377) 0.007 64.514 (1.131–3680.239) 0.04
*After adjusting coronary artery occlusive disease, prior statin use, and severe cerebral stenotic lesion.
guidelines for management of blood cholesterol (35). Further
investigations should focus on the optimal cholesterol level that
may reduce the burden of ICAS.
The present study has several limitations. It was a cross-
sectional study, which makes it difficult to establish the causal
association. The sample size was small, since we included patients
who were admitted for symptomatic acute ischemic stroke and
underwent VW-MRI at a single center. Enhancement of arterial
wall could also be associated with other conditions mimicking
ICAS such as age-related vasa vasorum in the intracranial
arteries, normal enhancement of veins, and slow flow artifacts
(9, 19). However, efforts were made in the present study to
distinguish ICAS with its pitfalls based on the pattern and the
topographic distribution of vessel wall enhancement. We applied
the black-blood technique to distinguish slow flow artifacts from
arterial wall thickening. Hence, we believe that the possibility of
including pathologies other than ICAS was small. Lastly, because
the lipid profiles could be changed during acute stroke period,
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the pattern of enhancement could be changed along with the
changing lipid profiles. However, we could not investigate the
dynamic change of enhancement of VWMRI in this study.
The present study demonstrated that the presence and
severity of enhancement of ICAS, especially the culprit
lesion, tends to be associated with dyslipidemic conditions.
Our findings suggest that strict lipid modification may be
effective in the management of ICAS. Further longitudinal
studies concentrating on the change in the ICAS burden
after lipid modification therapy are required to fully address
this issue.
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